Table 2.
Immune-related adverse events (irAEs) by characteristics and resolution rates.
| IrAEs Category | No. of Patients, n = 109 | No. of Resolved Events, n = 148, (%) | |
|---|---|---|---|
| Any Grade, n (%) | Grade 3–5, n (%) | ||
| Any irAEs | 55 (50.5%) | 16 (14.7%) | 104 (70.3%) |
| Single site irAEs | 17 (15.6%) | / | |
| Multiple site irAEs | 38 (34.9%) | / | |
| Pulmonary | |||
| Pneumonitis | 14 (12.8%) | 4 (3.7%) | 8 (57.1%) |
| Cardiovascular | |||
| Myocardial ischemia | 1 (0.9%) | 0 | 1 (100.0%) |
| Atrial fibrillation | 2 (1.8%) | 2 (1.8%) | 1 (50.0%) |
| Hypertension | 1 (0.9%) | 1 (0.9%) | 0 |
| Gastrointestinal | |||
| Diarrhea | 1 (0.9%) | 0 | 1 (100.0%) |
| Amylase increase | 2 (1.8%) | 2 (1.8%) | 1 (50.0%) |
| Hepatic | |||
| ALT increase | 13 (11.9%) | 2 (1.8%) | 11 (84.6%) |
| AST increase | 10 (9.2%) | 2 (1.8%) | 7 (70.0%) |
| γGT increase | 13 (11.9%) | 3 (2.8%) | 10 (76.9%) |
| Blood bilirubin increase | 2 (1.8%) | 1 (0.9%) | 2 (100.0%) |
| Renal | |||
| Nephritis | 3 (2.8%) | 0 | 1 (33.3%) |
| Creatinine increase | 2 (1.8%) | 0 | 1 (50.0%) |
| Hyperkalemia | 1 (0.9%) | 0 | 1 (100.0%) |
| Musculoskeletal | |||
| Myalgia | 4 (3.7%) | 0 | 3 (75.0%) |
| Arthralgia | 1 (0.9%) | 0 | 1 (100.0%) |
| Endocrine | |||
| Hypothyroidism | 17 (15.6%) | 0 | 4 (23.5%) |
| TSH increase | 1 (0.9%) | 0 | 1 (100.0%) |
| Hyperthyroidism | 13 (11.9%) | 0 | 12 (92.3%) |
| Hyperglycemia | 3 (2.8%) | 2 (1.8%) | 1 (33.3%) |
| Skin | |||
| Rash | 18 (16.5%) | 2 (1.8%) | 15 (83.3%) |
| Pruritus | 15 (13.8%) | 2 (1.8%) | 13 (86.7%) |
| Eye | |||
| Blurred vision | 1 (0.9%) | 0 | 1 (100.0%) |
| Neurology | |||
| Numb | 2 (1.8%) | 0 | 0 |
| Others | |||
| Infusion reaction | 1 (0.9%) | 1 (0.9%) | 1 (100.0%) |
| Pyrexia | 7 (6.4%) | 0 | 7 (100.0%) |
ALT, Alanine transaminase; AST, Aspartate aminotransferase; γGT, Gamma-Glutamyltransferase; TSH, Thyroid Stimulating Hormone.